The Guest Editors have put together an issue of clinical reviews that provides the most current look at PBC. Authors, all experts in their respective areas, have submitted articles in the following areas: Changes in epidemiology of PBC; Genetic and epigenetics in PBC; Role of bile acids and the bicarbonate umbrella in the pathogenesis of PBC; Current treatment options in PBC; Work in progress: Drugs in development; Natural history of PBC in the UDCA era: Role of scoring systems; Treatment of Pruritus: Tricks of the trade; Chronic complications of cholestasis: Work-up and Management; Individualizing care: Management beyond medical therapy; Role of liver biopsy: When to do, how to stage; AMA-negative PBC: Is it really the same as AMA-positive PBC?; New thoughts on Overlap syndrome with auto-immune hepatitis; and Current status of liver transplantation for PBC.

Since the publication of the first edition, there have been advances in both the diagnosis and the management of many of the cholestatic liver diseases. Cholestatic Liver Disease, Second Edition thoroughly updates the topics previously addressed, such as primary biliary cirrhosis, primary sclerosing cholangitis, and cholestatic variants of drug hepatotoxicity and viral disease. New treatments, such as the development of the farnesoid X receptor agonists for the treatment of PBC, are highlighted. Current guidelines and areas of uncertainty are also covered. Additionally, new chapters have been added to reflect the changing landscape of cholestatic liver disease. Cholestatic Liver Disease, Second Edition is a concise yet comprehensive summary of the current status of the field and is of value to clinicians and researchers interested in patients with cholestatic liver disease provide that will help to guide patient management and stimulate investigative efforts.

Since the publication of the first edition, there have been advances in both the diagnosis and the management of many of the cholestatic liver diseases. Cholestatic Liver Disease, Second Edition thoroughly updates the topics previously addressed, such as primary biliary cirrhosis, primary sclerosing cholangitis and cholestatic variants of drug hepatotoxicity and viral disease. New treatments, such as the development of the farnesoid X receptor agonists for the treatment of PBC, are highlighted. Current guidelines and areas of uncertainty are also covered. Additionally, new chapters have been added to reflect the changing landscape of cholestatic liver disease. Cholestatic Liver Disease, Second Edition is a concise yet comprehensive summary of the current status of the field and is of value to clinicians and researchers interested in patients with cholestatic liver disease provide that will help to guide patient management and stimulate investigative efforts.